Medpace Holdings, Inc. (NASDAQ:MEDP) is Alpine Peaks Capital LP's 6th Largest Position

Alpine Peaks Capital LP trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 26.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,106 shares of the company's stock after selling 7,403 shares during the period. Medpace comprises 5.8% of Alpine Peaks Capital LP's investment portfolio, making the stock its 6th biggest holding. Alpine Peaks Capital LP owned approximately 0.07% of Medpace worth $7,012,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. R Squared Ltd purchased a new stake in Medpace during the fourth quarter worth $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace during the 4th quarter worth $31,000. Jones Financial Companies Lllp boosted its position in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC grew its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. This represents a 36.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.30% of the company's stock.

Medpace Price Performance

MEDP stock traded up $5.63 during trading on Tuesday, reaching $303.81. 174,997 shares of the stock traded hands, compared to its average volume of 433,918. The firm has a market capitalization of $8.73 billion, a PE ratio of 24.05, a P/E/G ratio of 3.81 and a beta of 1.46. The business's 50 day moving average price is $312.88 and its 200-day moving average price is $331.26. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same quarter in the previous year, the business earned $3.20 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on MEDP shares. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, Robert W. Baird lowered their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of "Hold" and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.